PolyPid to get $2.6M upfront under license deal with Advanz for D-PLEX in Europe
PolyPid (NASDAQ:PYPD) signed an exclusive licensing agreement for its lead drug candidate D-PLEX100 in Europe with U.K.-based Advanz Pharma (OTCPK:CXRXF). D-PLEX100 is used for preventing surgical sit
Seeking AlphaAug 3, 2022 09:16 ET
Intercept Pharma to sell ex-U.S. rights for Ocaliva to Advanz Pharma
Commercial-stage biotech, Intercept Pharmaceuticals (NASDAQ:ICPT) announced an agreement with Europe-based Advanz Pharma (OTCPK:CXRXF) on Thursday to sell some of its foreign units and rights regardin
Seeking AlphaMay 5, 2022 08:15 ET
Nordic Capital Acquires Specialty Pharmaceutical Company ADVANZ PHARMA In Deal Worth $846 Million CXRXF
*DJ Nordic Capital Acquires Specialty Pharmaceutical Company ADVANZ PHARMA In Deal Worth $846 Million CXRXF (MORE TO FOLLOW) Dow Jones Newswires June 01, 2021 05:13 ET (09:13 GMT) Copyright (
Dow Jones NewswiresJun 1, 2021 05:13 ET
No Data
No Data